Clinical trials: Liver Diseases, Alcoholic
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Non-Alcoholic Fatty Liver Disease
NASH and Coronary Disease
Although the clinical relationship between NAFLD/NASH and cardiovascular (CV) risk is now well established, there is very little awareness of the hepatic disease and the way it may contribute to increased CV risk in patients seen…
- Trial name
- CORO-NASH (NCT03819283)
- Testing
- Hepatic evaluation
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NASH - Nonalcoholic Steatohepatitis
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
This is a Phase 2a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in…
- Trial name
- NCT05415722
- Testing
- TERN-501, TERN-101
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Non Alcholic Fatty Liver Disease
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
This is a Phase III, multicentre, randomized, double-blind, placebo-controlled, interventional study designed to evaluate the efficacy and safety of a standardized fraction of Picrorhiza kurroa Royal Ex Benth (Picroliv®) in…
- Trial name
- NCT07452744
- Testing
- Picroliv
- Where
- 6 sites in India
- Volunteers
- 170 people
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
Non-alcholic Fatty Liver Disease
Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis
Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK) activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1 (S6K1) inhibition.
- Trial name
- NCT02068339
- Testing
- Oltipraz 1 (90mg), Oltipraz 2 (120mg)
- Where
- 5 sites in South Korea
- Volunteers
- 283 people
- Sponsor
- PharmaKing
Alcoholic Liver Disease
Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Fermented Protaetia brevitarsis seulensis powder on Alcohol-induced Liver Disease in adults for 8 weeks.
- Trial name
- NCT04320199
- Testing
- Fermented Protaetia brevitarsis seulensis powder group
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pusan National University Yangsan Hospital
NAFLD, NASH - Nonalcoholic Steatohepatitis
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
Magnetic resonance imaging (MRI) is used to measure liver fat content and fatty tissues in the body, and magnetic resonance elastography (MRE) is used to measure liver stiffness.
- Trial name
- NCT04591106
- Testing
- Magnetic resonance imaging (MRI), Magnetic resonance elastography (MRE), Prototype MRE soft flexible passive transducer paddle
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Non-Alcoholic Fatty Liver Disease
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease.
- Trial name
- MODIFY (NCT05209100)
- Testing
- Sigmoidoscopy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Non-Alcoholic Steatohepatitis
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
The term non-alcoholic fatty liver disease (NAFLD) is used to describe a range of chronic liver diseases that range from steatosis to steatohepatitis, advanced fibrosis, cirrhosis, or excessive alcohol consumption or other causes…
- Trial name
- NCT05065593
- Testing
- resistance and aerobic exercise, physical activity recommendation
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
NAFLD
Copeptin and Nonalcoholic Fatty Liver Disease
Copeptin, a surrogate marker for vasopressin, has been found to be elevated in metabolic disorders including obesity and diabetes, which are disorders both associated with nonalcoholic fatty liver disease (NAFLD), and therefore…
- Trial name
- NCT03254563
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Obesity, Diabetes Mellitus, Type 2
Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD
This study is designed as a prospective pilot study for longitudinal assessment of fecal microbiome related to medical and surgical weight loss.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, NAFLD
- Trial name
- NCT04263376
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
NAFLD
Lifestyle Modification in the Treatment of NAFLD.
The project will study the impact of individually tailored lifestyle counselling compared to standard care on the parameters of NAFLD/NASH in patients with metabolic syndrome.
- Trial name
- NCT05816915
- Testing
- Cognitive behavioral therapy
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- General University Hospital, Prague
Alcoholic Liver Disease
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
Alcoholic liver disease represents the major health issues and it ranges from simple steatosis to cirrhosis. There is a paucity of data to support the allopathic intervention among these group of patients.
- Trial name
- NCT03503708
- Testing
- Livitol-70
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Composite Interceptive Med Science
Obesity, NAFLD
ER Stress in NAFLD
The investigators overall hypothesis is that exacerbation of endoplasmic reticulum (ER) stress in the liver is associated with significant alterations in phosphatidylcholines that drive the NASH phenotype in obese humans.
- Trial name
- NCT01807910
- Testing
- methyl-D9-choline
- Where
- United States
- Sponsor
- Vanderbilt University
NAFLD, Liver Cirrhosis
Risk Factors for Advanced Fibrosis Among FLD Patients
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication.
- Conditions
- NAFLD, Liver Cirrhosis, Diabetes Mellitus, Type 2
- Trial name
- FLD_FU_HUS (NCT05971082)
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Healthy
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.
- Trial name
- NCT03597217
- Testing
- PF-05221304
- Where
- Japan
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Steatohepatitis, Type 2 Diabetes Mellitus
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT02769091)
- Testing
- TEV-45478
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
NAFLD Cirrhosis
Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
The role of Dapagliflozin in the improvement in CKD in both diabetic and non-diabetic patients has been evaluated in the past. SGLT2i have also been found to be beneficial in NAFLD patients in improving the liver function…
- Trial name
- NCT05849220
- Testing
- Dapagliflozin, Standard of Care
- Where
- India
- Volunteers
- 144 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.